Navigation Links
GiiResearch.com: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018
Date:12/1/2011

e.

The majority of participants in the PCOS therapeutics pipeline are institutions or universities. Company participation is low because most of the drugs under trial are generics and already being used for this indication, either alone or in combination. Therefore, the current pipeline products are unlikely to impact the market significantly.

Increasing Disease Population to Contribute to Market Growth

Patient population of PCOS is increasing due to a rise in co-morbid conditions such as diabetes, obesity and other cardiovascular complications. 60 million people are obese, a figure which almost doubled in the last 14 years (CDC study, Sept. 2006).

On average, 5%-10% of women suffer from PCOS. During the last decade, various programs have been created to spread awareness of the syndrome. In 2005, the American Association of Clinical Endocrinologists launched an awareness campaign to spread information regarding its complications and treatments. After this, the number of cases of self reported symptoms increased considerably.

Lack of Approved Drugs and Disease Modifiying Therapies a Barrier to PCOS Market Growth

The current PCOS therapeutics market has no specific approved products to treat the syndrome. The current drugs which are used to treat the associated condition of PCOS are generic and off-label products. Therefore the presence of generics poses a threat for the growth of the market both now and in the future. The unavailablilty of approved drug and usage of generic and off-label drugs which have low costs of therapy further reduces the revenue generated by the market.

The market mainly relies upon treating associated conditions of PCOS by using various generic and off-label products, and there is no single product which can treat all the conditions of PCOS. Current therapies are less efficacious, so patient and physician satisfaction is low. There are few companies involved in the
'/>"/>

SOURCE Global Information, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
2. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
3. A New Target in Polycystic Kidney Disease
4. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
5. NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
6. OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment
7. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
8. Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
9. BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers
10. EGEN, Inc. Announces that Phase II Clinical Trial for Advanced Ovarian Cancer is Open for Enrollment
11. For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  VentiRx Pharmaceuticals, Inc., a ... development and commercialization of novel Toll-like receptor ... U.S. Food and Drug Administration (FDA) has ... of motolimod (VTX-2337) when administered in combination ... treatment of women with ovarian cancer whose ...
(Date:9/2/2014)... , Sept. 2, 2014 Bluegrass ... company focused on innovating lifesaving devices and methods ... of Dr. Gabriele Niederauer , a seasoned ... Following the recent closure of Series A financing, ... the Surfacer™ Inside-Out Access Catheter System, a proprietary ...
(Date:9/2/2014)... LAUSANNE , Switzerland , ... after receiving ISO 13485 accreditation, Sophia Genetics has become ... mark for the clinical use of a Next Generation Sequencing ... assurance certification represents an important step in raising ... diagnosis, and brings Sophia Genetics, world-leading Data Driven ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing 2
... 20 The District of Columbia Patients, Cooperative ... the District of Columbia, has submitted comments to the ... on proposed regulations announced 45 days ago.   ... http://www.dcpatients.org/DCPC_comments.pdf along with the comments of cannabis ...
... NewBridge Pharmaceuticals FZ-LLC of Dubai, UAE announced today that ... Executive Officer and a member of the company,s Board ... joins NewBridge after a career extending over 29 years ... positions covering many geographies including; US, Europe, and Middle ...
Cached Medicine Technology:DC Patients' Cooperative Urges Changes to the Proposed Medical Cannabis 'Marijuana' Regulations 2NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments 2NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments 3
(Date:9/2/2014)... September 02, 2014 As an industry transformation ... an industry and predict change. Fortunately for him, that valuable ... to identify markets that are eager for change — such ... the hearing aid market indicated it was ripe for better ... Sapio explained. As a result, he took matters into his ...
(Date:9/2/2014)... available in Spanish . ... through an experiment conducted on rats, that hyperproteic diets could ... for groups with bone disease problems, such as the elderly ... vegetal proteinin the case of the present study, soy proteinis ... former increased the level of calcium in bones by as ...
(Date:9/2/2014)... in their work care for patients who are dying. ... that many nurses in training feel unprepared and anxious ... end-of-life care. , Scientists from the Sahlgrenska Academy have ... the University of Skvde and the Ersta Skndal University ... for dying patients, their ideas about how to support ...
(Date:9/2/2014)... 2014 Catalent, the leading global ... for drugs, biologics and consumer health products, today ... Eli Lilly’s growth, it is to install new ... Philadelphia Clinical Supply Center of Excellence. , Catalent ... its clinical supply facility in Schorndorf, Germany, providing ...
(Date:9/2/2014)... 02, 2014 Splashtop Inc. , ... partnership with NTT DoCoMo to deliver Splashtop ... Splashtop Business Lite is included in NTT DoCoMo’s “Business ... desktop software that empower users to remote access their ... garnered over 18 million users worldwide. Splashtop delivers ...
Breaking Medicine News(10 mins):Health News:David Sapio Launches Zounds Hearing Franchise 2Health News:Study conducted on rats suggests that hyperproteic diets can be beneficial for bones 2Health News:Many nurses unprepared to meet dying patients 2Health News:Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions 2Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2
... discovery in a Florida State University College of Medicine ... to one day help scientists learn how to stop ... are forming. , Jamila Horabin, associate professor of biomedical ... four-year, $1.2 million grant from the National Institutes of ...
... develop a custom solution for The Kidney Foundation of Canada that will ... ... (Vocus) January 9, 2009 -- Blackbaud, Inc. (Nasdaq: BLKB ) today ... of Canada that will create a unified national CRM and web presence., ...
... (PHILADELPHIA) Efforts to fight the toll of cardiac ... CPR education and improvement, public defibrillation programs, and quicker ... Pennsylvania School of Medicine reveals that the hospital where ... key role in their chances of survival following these ...
... Both a Membership Card and Debit Card for Health-related ExpensesPITTSBURGH, ... inconvenience often associated with a Flexible Spending Account (FSA) with ... card - which is unique to Western Pennsylvania - serves ... a debit card for out-of-pocket health care expenses.The My ...
... More than 1,800 in Florida Alone ST. PETERSBURG, Fla., ... franchise, announced today the launch of its low-cost, home-based ... consumers containing their comprehensive medical history. eMed-ID is ... medical history on an easy-to-carry or wearable USB device. ...
... to tomorrow,s (and even today,s) health problems may be ... 2009 Consumer Electronics ShowLAS VEGAS, Jan. 9 ... technology changing the way we shop, listen to music, ... family. However, managing an illness or disability remains a ...
Cached Medicine News:Health News:Researcher wins $1.2 million grant for gene regulation work 2Health News:Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada 2Health News:Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada 3Health News:Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada 4Health News:Penn study: Chances of surviving cardiac arrest depend on where patients are treated 2Health News:Penn study: Chances of surviving cardiac arrest depend on where patients are treated 3Health News:UPMC Health Plan Introduces `MyFlex Advantage' Card 2Health News:UPMC Health Plan Introduces `MyFlex Advantage' Card 3Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 2Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 3Health News:Meridian Makes CES Good For Your Health 2
... The dual lumen ... a 1.2 mm inner ... ,Dual oval lumen catheters ... while maintaining maximum catheter ...
The mid-sized titanium port is about 3/4 the diameter and half the weight of the standard model. The silicone catheter has an I.D. of 1.0 mm....
The WaveMap provides immediate clinical decision making information with automatic calculation of pressure gradients and FFR measurements.,SmartWire Pressure Guide Wire - The intelligent choice in ...
... Used for vascular access. ... facilitates single wall puncture with ... sideport is visualized while maintaining ... Sideport exits the hub of ...
Medicine Products: